Drug Trial Radar · NCT06174779
A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
448
Actual
Start
Jan 3, 2024
Primary completion
Aug 14, 2025
Study completion Mar 13, 2026
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus
Conditions
- Obesity
Interventions
HM11260CDrug
Test drug
PlaceboDrug
Placebo drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percent change of body weight from baselineTime frame: baseline, 40 weeks
- The proportion of subjects achieving body weight loss ≥ 5% from baselineTime frame: baseline, 40 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kangbuk samsung hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.